A recently established investment firm based in Asia and backed by a large industrial family enterprise. The firm manages substantial capital and focuses on early-stage opportunities across life sciences and healthcare. The firm typically invests from Seed through Series B and evaluates opportunities globally. In addition to capital investment, the firm is interested in supporting international companies seeking expansion opportunities into the China market.
The firm’s investment activity is weighted primarily toward therapeutics, while also maintaining interest in diagnostics, medical technology, and AI-enabled healthcare solutions. Within therapeutics, the firm prioritizes highly innovative, next-generation approaches rather than incremental improvements. Areas of interest include advanced drug delivery technologies for mRNA and gene-editing therapies, particularly non-traditional delivery systems and platforms capable of targeting difficult tissues such as the brain. The firm also evaluates extracellular delivery technologies and next-generation cell therapy approaches designed to improve scalability, manufacturability, and cost efficiency. Modalities of interest include TCR-based platforms, NK cell technologies, and macrophage-targeting approaches. The firm is broadly indication-agnostic and is open to technically complex programs addressing major unmet medical needs.
The firm does not impose strict requirements regarding company structure or management team composition.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment